Annovis Closes $10 Million Offering

Annovis has successfully closed a $10 million offering, significantly extending its cash runway. This financing is crucial for advancing its Phase 3 Alzheimer's disease trial, with an NDA submission anticipated following a 6-month data readout in Q1 2027. The funding provides the necessary resources to reach key clinical milestones. The company's trial is reportedly 75% complete, underscoring the importance of this capital infusion for continued progress.